Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Alaunos Therapeutics Inc.
Headquarters: Houston, TX, United States of America
Website: https://alaunos.com/
Year Founded: 2005
Status: Public
Industry Sector: HealthTechnology
CEO: Dale Curtis Hogue, Jr., MBA
Number Of Employees: 1
Enterprise Value: $1,959,385
PE Ratio: -0.86
Exchange/Ticker 1: NASDAQ:TCRT
Exchange/Ticker 2: N/A
Latest Market Cap: $4,019,100
BioCentury | Oct 24, 2024
Data Byte
New modalities flood the EGFR pipeline
Bispecifics, ADCs and more compete to become the next-generation of EGFR-targeting agents
BioCentury | Jan 3, 2024
Management Tracks
Rimac leaving Sagimet as CFO
Plus: Harpoon names new legal, HR officers, and updates from Alimera, Alaunos and Novo Holdings
BioCentury | Aug 16, 2023
Regulation
Aug. 15 Quick Takes: April PDUFA for Carvykti in earlier stage MM
Plus: Nucleic acid company Impilo launches to treat solid tumors and updates from Galecto, Design, Arcellx, Amicus, Alaunos, Lidao
BioCentury | Feb 14, 2023
Data Byte
The IL-12 clinical pipeline: about as many modalities as molecules
The companies casting wide net in attempt to harness IL-12’s immune stimulation without its toxicity
BioCentury | Nov 1, 2022
Product Development
Neoantigens Part II: cell therapies
An overview of the growing field, company players and emerging data
BioCentury | Aug 23, 2022
Management Tracks
Wigginton to lead R&D at Bright Peak
Plus: a Mythic farewell for Nichols, Biswas joins CDR-Life as CMO and updates from Brii, Ansa, Kyverna, AskBio and more
BioCentury | Jan 28, 2022
Product Development
Jan. 27 Quick Takes: $100M raise is latest step in Zymeworks revival
Plus A first for bioelectronic therapies by Galvani, and updates from Moderna, Cue, Epizyme, Provention, Ziopharm
Items per page:
1 - 7 of 7